Last reviewed · How we verify
Tiragolumab and Atezolizumab IV FDC — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tiragolumab and Atezolizumab IV FDC (Tiragolumab and Atezolizumab IV FDC) — Hoffmann-La Roche.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tiragolumab and Atezolizumab IV FDC TARGET | Tiragolumab and Atezolizumab IV FDC | Hoffmann-La Roche | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tiragolumab and Atezolizumab IV FDC CI watch — RSS
- Tiragolumab and Atezolizumab IV FDC CI watch — Atom
- Tiragolumab and Atezolizumab IV FDC CI watch — JSON
- Tiragolumab and Atezolizumab IV FDC alone — RSS
Cite this brief
Drug Landscape (2026). Tiragolumab and Atezolizumab IV FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/tiragolumab-and-atezolizumab-iv-fdc. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab